Latest From NeuroPace Inc.
Total takings from October's venture financing deals may not have been the highest, but the $295m raised by the 20-plus transactions last month is enough for 2017 to trump 2016 in total deal value – with more room to widen the gap.
START-UP reviews five years of fundraising and exit activities for privately held medtech and diagnostics companies developing neurology treatments. Part 2 of our series on neuro-focused capital raising and bow-outs.
In recent years, medtech start-ups have made great strides in developing technologies to treat eye disease such as cataracts, diminishing vision, and even dry eye. But the greatest leaps – or the most life changing – may have been executed by companies such as Second Sight Medical Products Inc. and Wicab Inc. that are finding ways to actually help blind people see.
New Enterprise Associates surprised some by locking down $3.1 billion in new capital during a tight fundraising climate. General partner David Mott and partner Justin Klein share the firm’s investment approach.
- Implantable Devices
- Monitoring Equipment & Devices
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- NeuroPace Inc.
- Senior Management
Michael Favet, CEO
Rebecca L Kuhn, CFO & VP, Fin. & Admin.
Martha J Morrell, MD, CMO
Andre Marquette, Chief Commercial Officer
- Contact Info
Phone: (650) 237-2700
455 N. Bernardo Ave.
Mountain View, CA 94043
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.